The Current Ratio as of September 2024 (TTM) for Silence Therapeutics plc (SLN) is 9.83

According to Silence Therapeutics plc’s latest financial reports and current stock price. The company's current Current Ratio is 9.83. This represents a change of 22.60% compared to the average of 8.02 of the last 4 quarters.

Silence Therapeutics plc (SLN) Historical Current Ratio (quarterly & annually)

How has SLN Current Ratio performed in the past?

The mean historical Current Ratio of Silence Therapeutics plc over the last ten years is 13.14. The current 9.83 Current Ratio has changed 7.38% with respect to the historical average. Over the past ten years (40 quarters), SLN's Current Ratio was at its highest in in the March 2015 quarter at 60.63. The Current Ratio was at its lowest in in the September 2020 quarter at 0.

Silence Therapeutics plc (SLN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Silence Therapeutics plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Silence Therapeutics plc (SLN) Average Current Ratio

How has SLN Current Ratio performed in the past?

The current Current Ratio of Silence Therapeutics plc (SLN) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Silence Therapeutics plc (SLN) Current Ratio vs. Peers

How is SLN’s Current Ratio compared to its peers?

Silence Therapeutics plc’s Current Ratio is greater than Cidara Therapeutics, Inc. (4.25), greater than Applied Therapeutics, Inc. (2.30), greater than CytomX Therapeutics, Inc. (1.00), less than Shattuck Labs, Inc. (0), greater than C4 Therapeutics, Inc. (7.62), greater than Eliem Therapeutics, Inc. (5.09), less than Prelude Therapeutics Incorporated (60.41), greater than Monte Rosa Therapeutics, Inc. (7.83), greater than Opthea Limited (6.56), greater than Centessa Pharmaceuticals plc (2.94), less than Nuvalent, Inc. (13.29), less than Tarsus Pharmaceuticals, Inc. (17.44), greater than Genfit S.A. (7.03), greater than Avidity Biosciences, Inc. (2.94), less than IGM Biosciences, Inc. (15.78), greater than Cerevel Therapeutics Holdings, Inc. (7.06), less than Cullinan Oncology, Inc. (10.22), less than Mineralys Therapeutics, Inc. (28.87), less than null (11.20),

Build a custom stock screener for Silence Therapeutics plc (SLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Silence Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Silence Therapeutics plc (SLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Silence Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.